Gut bacteria and eye inflammation in children with uveitis
Studies gut bacteria signs in children with noninfectious uveitis.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Microbiome in Uveitis and Pediatric Inflammatory Diseases
- Status
- Not yet recruiting
- People taking part
- 500 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2028
- Type of study
- Observational, 3 groups
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children treated at Robert-Debré Hospital who have noninfectious uveitis (eye inflammation not caused by infection) or another childhood inflammatory disease. Healthy children, such as siblings of patients or children of hospital staff, can also join as a comparison group.
- Age
- 1 Day to 17 Years (under 18)
- Sex
- All sexes
- Disease stage
- Noninfectious uveitis, or a childhood inflammatory disease without uveitis: connective tissue disorders, granulomatosis, juvenile idiopathic arthritis or childhood vasculitis (inflamed blood vessels). Healthy children can join as controls.
Main reasons for not taking part
- The child or parents object to taking part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients under the age of 18 being treated at Robert-Debré Hospital
- Patients being treated for noninfectious uveitis, or with pediatric inflammatory diseases without uveitis (connective tissue disorders, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitides)
- The child and his or her parents have no objection to participating in the study
- Siblings of patients (family controls) or other healthy controls (children of hospital staff)
Who cannot take part
- -
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of the underlying disease. Studying these biological signatures in comparative cohorts could lead to a better understanding of the onset of uveitis and the development of targeted diagnostic and therapeutic strategies.
The 3 groups in the trial
- patients with noninfectious uveitis
including pediatric connective tissue disorders, granulomatosis, idiopathic juvenile arthritis without uveitis, pediatric vasculitis, and chronic inflammatory bowel diseases. These conditions were selected because of their inflammatory and/or autoimmune nature, making it possible to determine whether fecal peptidoglycan signatures
- patients with another inflammatory disease
without uveitis (connective tissue disease, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitis, chronic inflammatory bowel disease)
- healthy children living in the same household as those who are sick
Siblings of patients or children of hospital staff, who may be included as healthy control groups
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Gut Microbiota in Uveitis and Pediatric Inflammatory Diseases: Identification of the Fecal Peptidoglycan Signature
- Plain-language title
- Gut bacteria and eye inflammation in children with uveitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 21 October 2026